Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Core Insights - Avidity Biosciences, Inc. will present late-breaking oral and poster presentations at the 30th Annual International Congress of the World Muscle Society (WMS) from October 7-11, 2025, in Vienna, Austria [1][2] - The data to be presented will build on positive findings from September 2025, showing reversal of disease progression and significant improvement in functional measures for Duchenne muscular dystrophy (DMD) patients treated with delpacibart zotadirsen (del-zota) [2][7] - Del-zota is still investigational and has not received FDA approval, with its safety and efficacy yet to be established [2][5] Presentation Details - Oral presentation by Kevin M. Flanigan, M.D., scheduled for October 11, 2025, focusing on functional and patient-reported outcomes in DMD patients [7] - Poster presentation by Aravindhan Veerapandiyan, M.D., on October 8, 2025, highlighting increased dystrophin and improved muscle integrity markers in DMD patients [7] Company Overview - Avidity Biosciences is focused on developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs), aiming to improve treatment for rare muscle diseases [5] - The company has demonstrated successful targeted delivery of RNA into muscle and is advancing clinical programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy [5] - Avidity is also expanding its pipeline to include precision cardiology candidates and programs in cardiology and immunology through partnerships [5]